Afrezza their FDA approved drug is finally starting to generate sales after being fda approved years ago.
They are also working on several other products for 2020.
Huge accumulation range and due to very aggressive short sellers flooding the market with over 40 million additional shares over the years.
All of these short sales will eventually be pressured to rebuy rapidly driving up price. There are also warrants that were delayed and expire in July.
With the healthcare sector and biotech improving at a rapid pace, an effective product, all the catalysts are there.